J Korean Neuropsychiatr Assoc.  2010 Nov;49(6):546-552.

Korean Medication Algorithm Project for Generalized Anxiety Disorder 2009 (I) : Initial Treatment Strategy

Affiliations
  • 1Department of Psychiatry, Inje University College of Medicine, Seoul, Korea.
  • 2Department of Psychiatry, Sungkyunkwan University College of Medicine, Seoul, Korea.
  • 3Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea.
  • 4Department of Psychiatry, Chonbuk National University Medical School, Jeonju, Korea.
  • 5Department of Psychiatry, School of Medicine, CHA University, Seoul, Korea. freud@chol.com

Abstract


OBJECTIVES
This study investigated the consensus about treatment strategies for the initial treatment of generalized anxiety disorder (GAD). This issue represents one of the subjects addressed by the Korean Medication Algorithm Project for GAD in Korea.
METHODS
The executive committee of the Korean Medication Algorithm Project for GAD, supported by The Korean Association of Anxiety Disorders, developed questionnaires about treatment strategies for patients with GAD, based on guidelines or algorithms and clinical trial studies previously published in foreign countries, especially by the International Psychopharmacology Algorithm Project, the National Institute for Clinical Excellence, and the Canadian Psychiatric Association. Fifty-five (64%) of 86 experts on a committee reviewing GAD in Korea responded to the questionnaires. We classified the consensus of expert opinions into three categories (first-line, second-line, and third-line treatment strategies) and identified the treatment of choice according using a Chi-square test and a 95% confidence interval.
RESULTS
For the initial treatment of GAD, antidepressant monotherapy and the combination of antidepressants and benzodiazepines as anxiolytics were recommended as the first line strategies. Escitalopram, paroxetine CR and venlafaxine XR were selected as first-line antidepressant treatments, and alprazolam, clonazepam and lorazepam were the preferred benzodiazepines. The mean starting doses and mean maximum doses of the drugs were 7.55+/-3.09 mg and 24.91+/-8.14 mg for escitalopram, 12.57+/-2.83 mg and 44.76+/-15.00 mg for paroxetine CR, and 46.81+/-16.74 mg and 223.32+/-60.64 mg for venlafaxine XR.
CONCLUSION
These results, which reflect recent studies and clinical experiences, may provide guidelines for the initial.

Keyword

Generalized anxiety disorder; Pharmacotherapy; Algorithm; Initial treatment strategy

MeSH Terms

Alprazolam
Anti-Anxiety Agents
Antidepressive Agents
Anxiety
Anxiety Disorders
Benzodiazepines
Citalopram
Clonazepam
Consensus
Cyclohexanols
Expert Testimony
Humans
Korea
Lorazepam
Paroxetine
Psychopharmacology
Surveys and Questionnaires
Venlafaxine Hydrochloride
Alprazolam
Anti-Anxiety Agents
Antidepressive Agents
Benzodiazepines
Citalopram
Clonazepam
Cyclohexanols
Lorazepam
Paroxetine
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr